Long-term results in children with standard risk acute lymphoblastic leukaemia treated with 5.0 g/m2 versus 3.0 g/m2 methotrexate i.v. according to the modified ALL-BFM 90 protocol. The report of Polish paediatric Leukemia/lymphoma study group

Abstract

Purpose: A non objective randomised, retrospective study was performed to assess and compare the effi cacy of two different high doses of methotrexate (HD-MTX) in combination with intrathecal therapy in children with standard risk (SR) ALL as central nervous system (CNS) preventive therapy in a place of cranial radiation.Patients and methods: Between July 1993 and April 2002, in 650 children standard risk (SR) ALL were diagnosed and treated in Poland according to the modifi ed ALL-BFM 90 protocol. Methotrexate was used in the dose of either 3.0 g/m 2 (group A) or 5.0 g/m 2 (group B) four times in two week intervals during consolidation (protocol M).Results: Probability for 10-year event-free survival (pEFS) and relapse-free survival (pRFS) for all evaluated patients (n = 611) was 0.77 ± 0.02 and 0.82 ± 0.02, respectively. EFS probability for group A (n = 411) was 0.73 ± 0.03 and for group B (n = 200) -0.85 ± 0.04, whilst RFS probability for group A was 0.79 ± 0.04 and for group B -0.89 ± 0.03, and these differences proved statistically signifi cant (P = 0.0050 and P = 0.0012). In multivariate analysis, T-cell immunophenotype (P = 0.0046) and age older than 10 years (P = 0.0250) had a signifi cantly adverse impact on the outcome.Conclusions: HD-MTX used in dose 5.0 g/m 2 has been found to be more eff ective in the treatment of SR ALL in children than HD-MTX in dose 3.0 g/m 2 .Keywords: Standard risk acute lymphoblastic leukaemia, children, prophylaxis of central nervous system, high dose methotrexate.Long-term results in children with standard risk acute lymphoblastic leukaemia treated with 5.0 g/m 2 versus 3.0 g/m 2 methotrexate i.v. according to the modifi ed ALL-BFM 90 protocol.

GSTT1null and rs156697 Polymorphism in GSTO2 Influence the Risk and Therapeutic Outcome of B-Acute Lymphoblastic Leukemia Patients

“…Details were collected by personal interaction with the patients, and laboratory parameters were recorded from the CBC/bone marrow reports. Patients were risk stratified into low-, medium, and high-risk groups and treated according to modified BFM-95 protocol ( 24 , 25 ). All the patients were evaluated at baseline, after consolidation, and during as well as after maintenance stage of treatment for their response to chemotherapy.…”

Significance and implications of FHIT gene expression and promoter hypermethylation in acute lymphoblastic leukemia (ALL)

“…ALL patients were categorized according to the French & British American classification (FAB) and WHO classification of acute leukemia. ALL patients were classified into different set of risk groups and treatment was given as per the modified BFM-95 protocol [ 23 ]. Peripheral blood samples (2–3 ml) were taken from all the patients and from age and sex matched healthy controls with no signs of any hematological/and or any other malignancy from the Out Patients Department of SKIMS.…”